Faithfull modeling of PTEN loss driven diseases in the mouse

Current Topics in Microbiology and Immunology

Volumn 347, Issue 1, 2010, Pages 135-168

  Nardella, Caterina ^a   Carracedo, Arkaitz ^a   Salmena, Leonardo ^a   Pandolfi, Pier Paolo ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P53; PYRUVATE DEHYDROGENASE KINASE; REGULATOR PROTEIN; RHEB PROTEIN; TRANSCRIPTION FACTOR ERG; TUBERIN; TUBEROUS SCLEROSIS COMPLEX 1 PROTEIN; UNCLASSIFIED DRUG; PTEN PROTEIN, MOUSE;

ARTICLE; BRAF GENE; BRAIN TUMOR; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GENETICS; DISEASE COURSE; DISEASES; GENE; GENE INACTIVATION; GENE LOSS; GENETIC MODEL; GENETIC SCREENING; HUMAN; IN VIVO STUDY; MELANOMA; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEFECT; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PTEN GENE; TRANSCRIPTION REGULATION; ANIMAL; BREAST TUMOR; DISEASE MODEL; FEMALE; MALE; MOUSE; PHYSIOLOGY; PROSTATE TUMOR; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BRAIN NEOPLASMS; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; PHOSPHATIDYLINOSITOL 3-KINASES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79551516441     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/82-2010-62     Document Type: Article

References (188)

1. Abate-Shen C, Banach-Petrosky WA, Sun X, Economides KD, Desai N, Gregg JP, Borowsky AD, Cardiff RD, Shen MM (2003) Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. Cancer Res 63:3886-3890 (Pubitemid 36917899)
2. Abel TW, Baker SJ, Fraser MM, Tihan T, Nelson JS, Yachnis AT, Bouffard JP, Mena H, Burger PC, Eberhart CG (2005) Lhermitte-Duclos disease: a report of 31 cases with immunohistochemical analysis of the PTEN/AKT/mTOR pathway. J Neuropathol Exp Neurol 64:341-349 (Pubitemid 40489561)
3. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, Cohen P (1997) Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 7:261-269 (Pubitemid 27176852)
4. Ali IU, Schriml LM, Dean M (1999) Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst 91:1922-1932
5. Alimonti A, Carracedo A, Clohessy JG, Trotman LC, Nardella C, Egia A, Salmena L, Sampieri K, Haveman WJ, Brogi E, Richardson AL, Zhang J, Pandolfi PP (2010) Subtle variations in Pten dose determine cancer susceptibility. Nat Genet 42(5):454-458
6. Amundadottir LT, Sulem P, Gudmundsson J, Helgason A, Baker A, Agnarsson BA, Sigurdsson A, Benediktsdottir KR, Cazier JB, Sainz J et al (2006) A common variant associated with prostate cancer in European and African populations. Nat Genet 38:652-658 (Pubitemid 43927306)
7. Anzelon AN, Wu H, Rickert RC (2003) Pten inactivation alters peripheral B lymphocyte fate and reconstitutes CD19 function. Nat Immunol 4(3):287-294 (Pubitemid 36322140)
8. Backman SA, Stambolic V, Suzuki A, Haight J, Elia A, Pretorius J, Tsao MS, Shannon P, Bolon B, Ivy GO, Mak TW (2001) Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease. Nat Genet 29:396-403 (Pubitemid 34326689)
9. Backman SA, Ghazarian D, So K, Sanchez O, Wagner KU, Hennighausen L, Suzuki A, Tsao MS, Chapman WB, Stambolic V, Mak TW (2004) Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten. Proc Natl Acad Sci USA 101:1725-1730 (Pubitemid 38234221)
10. Balmanno K, Cook SJ (2009) Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ 16:368-377
11. Bayascas JR, Leslie NR, Parsons R, Fleming S, Alessi DR (2005) Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN(+/-) mice. Curr Biol 15:1839-1846 (Pubitemid 41501519)
12. Birck A, Ahrenkiel V, Zeuthen J, Hou-Jensen K, Guldberg P (2000) Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies. J Invest Dermatol 114:277-280 (Pubitemid 30417761)
13. Bose S, Wang SI, Terry MB, Hibshoosh H, Parsons R (1998) Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas. Oncogene 17:123-127 (Pubitemid 28360536)
14. Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser TC, Willi N, Mihatsch MJ, Sauter G, Kallioniemi OP (1999) Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 59:803-806 (Pubitemid 29086730)
15. Butler MG, Dasouki MJ, Zhou XP, Talebizadeh Z, Brown M, Takahashi TN, Miles JH, Wang CH, Stratton R, Pilarski R, Eng C (2005) Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. J Med Genet 42:318-321 (Pubitemid 40523954)
16. Buxbaum JD, Cai G, Chaste P, Nygren G, Goldsmith J, Reichert J, Anckarsater H, Rastam M, Smith CJ, Silverman JM, Hollander E, Leboyer M, Gillberg C, Verloes A, Betancur C (2007) Mutation screening of the PTEN gene in patients with autism spectrum disorders and macrocephaly. Am J Med Genet B Neuropsychiatr Genet 144B:484-491 (Pubitemid 46983159)
17. Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG, Jen J, Isaacs WB, Bova GS, Sidransky D (1997) Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 57:4997-5000 (Pubitemid 27498107)
18. Cairns P, Evron E, Okami K, Halachmi N, Esteller M, Herman JG, Bose S, Wang SI, Parsons R, Sidransky D (1998) Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene 16:3215-3218 (Pubitemid 28318794)
19. Cantley LC, Neel BG (1999) New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96:4240-4245 (Pubitemid 29190320)
20. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J, Pandolfi PP (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118:3065-3074
21. Carver BS, Tran J, Chen Z, Carracedo-Perez A, Alimonti A, Nardella C, Gopalan A, Scardino PT, Cordon-Cardo C, Gerald W, Pandolfi PP (2009a) ETS rearrangements and prostate cancer initiation. Nature 457:E1, discussion E2-E3
22. Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, Alimonti A, Nardella C, Varmeh S, Scardino PT, Cordon-Cardo C, Gerald W, Pandolfi PP (2009b) Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 41:619-624
23. Celebi JT, Shendrik I, Silvers DN, Peacocke M (2000) Identification of PTEN mutations in metastatic melanoma specimens. J Med Genet 37:653-657
24. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W, Cordon-Cardo C, Pandolfi PP (2005) Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436:725-730 (Pubitemid 41117277)
25. Chen ML, Xu PZ, Peng XD, Chen WS, Guzman G, Yang X, Di Cristofano A, Pandolfi PP, Hay N (2006) The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/-mice. Genes Dev 20:1569-1574 (Pubitemid 43901096)
26. Chen Z, Carracedo A, Lin HK, Koutcher JA, Behrendt N, Egia A, Alimonti A, Carver BS, Gerald W, Teruya-Feldstein J, Loda M, Pandolfi PP (2009) Differential p53-independent outcomes of p19(Arf) loss in oncogenesis. Sci Signal 2:ra44
27. Chiariello E, Roz L, Albarosa R, Magnani I, Finocchiaro G (1998) PTEN/MMAC1 mutations in primary glioblastomas and short-term cultures of malignant gliomas. Oncogene 16:541-545 (Pubitemid 28062082)
28. Chin L, Garraway LA, Fisher DE (2006) Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev 20:2149-2182
29. Ciraolo E, Iezzi M, Marone R, Marengo S, Curcio C, Costa C, Azzolino O, Gonella C, Rubinetto C, Wu H et al (2008) Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development. Sci Signal 1:ra3
30. Crackower MA, Oudit GY, Kozieradzki I, Sarao R, Sun H, Sasaki T, Hirsch E, Suzuki A, Shioi T, Irie-Sasaki J et al (2002) Regulation of myocardial contractility and cell size by distinct PI3KPTEN signaling pathways. Cell 110(6):737-749 (Pubitemid 35283963)
31. Currie RA,Walker KS, Gray A, DeakM, Casamayor A, Downes CP, Cohen P, Alessi DR, Lucocq J (1999) Role of phosphatidylinositol 3,4,5-trisphosphate in regulating the activity and localization of 3-phosphoinositide-dependent protein kinase-1. Biochem J 337(Pt 3):575-583
32. Dahia PL (2000) PTEN, a unique tumor suppressor gene. Endocr Relat Cancer 7:115-129 (Pubitemid 30609989)
33. Dahia PL, Marsh DJ, Zheng Z, Zedenius J, Komminoth P, Frisk T, Wallin G, Parsons R, Longy M, Larsson C, Eng C (1997) Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res 57:4710-4713 (Pubitemid 27468972)
34. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE Jr., You MJ, DePinho RA, McMahon M, Bosenberg M (2009) Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 41:544-552
35. Datta K, Bellacosa A, Chan TO, Tsichlis PN (1996) Akt is a direct target of the phosphatidylinositol 3-kinase. Activation by growth factors, v-src and v-Ha-ras, in Sf9 and mammalian cells. J Biol Chem 271:30835-30839 (Pubitemid 26404106)
36. De Marzo AM, Meeker AK, Zha S, Luo J, Nakayama M, Platz EA, Isaacs WB, Nelson WG (2003) Human prostate cancer precursors and pathobiology. Urology 62:55-62 (Pubitemid 37371890)
37. Denoyelle C, Abou-Rjaily G, Bezrookove V, Verhaegen M, Johnson TM, Fullen DR, Pointer JN, Gruber SB, Su LD, Nikiforov MA, Kaufman RJ, Bastian BC, Soengas MS (2006) Antioncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat Cell Biol 8:1053-1063 (Pubitemid 44473600)
38. Depowski PL, Rosenthal SI, Ross JS (2001) Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol 14:672-676 (Pubitemid 32667211)
39. Dhillon AS, Hagan S, Rath O, Kolch W (2007) MAP kinase signalling pathways in cancer. Oncogene 26:3279-3290 (Pubitemid 46763021)
40. Dhomen N, Reis-Filho JS, da Rocha Dias S, Hayward R, Savage K, Delmas V, Larue L, Pritchard C, Marais R (2009) Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 15:294-303
41. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP (1998) Pten is essential for embryonic development and tumour suppression. Nat Genet 19:348-355 (Pubitemid 28357906)
42. Di Cristofano A, De Acetis M, Koff A, Cordon-Cardo C, Pandolfi PP (2001) Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet 27:222-224 (Pubitemid 32157454)
43. Duerr EM, Rollbrocker B, Hayashi Y, Peters N, Meyer-Puttlitz B, Louis DN, Schramm J, Wiestler OD, Parsons R, Eng C, von Deimling A (1998) PTEN mutations in gliomas and glioneuronal tumors. Oncogene 16:2259-2264 (Pubitemid 28220656)
44. El Gedaily A, Bubendorf L, Willi N, Fu W, Richter J, Moch H, Mihatsch MJ, Sauter G, Gasser TC (2001) Discovery of new DNA amplification loci in prostate cancer by comparative genomic hybridization. Prostate 46:184-190 (Pubitemid 32142764)
45. Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R, Thomas GV, Sawyers CL (2003) Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4:223-238 (Pubitemid 37163836)
46. Engelman JA, Luo J, Cantley LC (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7:606-619 (Pubitemid 44100518)
47. Fang X, Yu S, Eder A, Mao M, Bast RC Jr., Boyd D, Mills GB (1999) Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway. Oncogene 18:6635-6640
48. Feilotter HE, Nagai MA, Boag AH, Eng C, Mulligan LM (1998) Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene 16:1743-1748 (Pubitemid 28175055)
49. Fisher GH, Wellen SL, Klimstra D, Lenczowski JM, Tichelaar JW, Lizak MJ, Whitsett JA, Koretsky A, Varmus HE (2001) Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev 15:3249-3262 (Pubitemid 34008191)
50. Ford-Hutchinson AF, Ali Z, Lines SE, Hallgrimsson B, Boyd SK, Jirik FR (2007) Inactivation of Pten in osteo-chondroprogenitor cells leads to epiphyseal growth plate abnormalities and skeletal overgrowth. J Bone Miner Res 22(8):1245-1259 (Pubitemid 351339707)
51. Fraser MM, Zhu X, Kwon CH, Uhlmann EJ, Gutmann DH, Baker SJ (2004) Pten loss causes hypertrophy and increased proliferation of astrocytes in vivo. Cancer Res 64:7773-7779 (Pubitemid 39446909)
52. Fraser MM, Bayazitov IT, Zakharenko SS, Baker SJ (2008) Phosphatase and tensin homolog, deleted on chromosome 10 deficiency in brain causes defects in synaptic structure, transmission and plasticity, and myelination abnormalities. Neuroscience 151:476-488
53. Fujisawa H, Reis RM, Nakamura M, Colella S, Yonekawa Y, Kleihues P, Ohgaki H (2000) Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas. Lab Invest 80:65-72 (Pubitemid 30067381)
54. Gao X, Zhang Y, Arrazola P, Hino O, Kobayashi T, Yeung RS, Ru B, Pan D (2002) Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat Cell Biol 4:699-704 (Pubitemid 34993706)
55. Garami A, Zwartkruis FJ, Nobukuni T, Joaquin M, Roccio M, Stocker H, Kozma SC, Hafen E, Bos JL, Thomas G (2003) Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell 11:1457-1466 (Pubitemid 36776533)
56. Garcia JM, Silva JM, Dominguez G, Gonzalez R, Navarro A, Carretero L, Provencio M, Espana P, Bonilla F (1999) Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype. Breast Cancer Res Treat 57:237-243
57. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, Lee C,Wagner SN, Li C, Golub TR, Rimm DL,MeyersonML, Fisher DE, Sellers WR (2005) Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436:117-122 (Pubitemid 40966196)
58. Gasser T (2007) Update on the genetics of Parkinson's disease. Mov Disord 22(Suppl 17): S343-S350 (Pubitemid 350134187)
59. Georgescu MM, Kirsch KH, Akagi T, Shishido T, Hanafusa H (1999) The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. Proc Natl Acad Sci USA 96:10182-10187 (Pubitemid 29422533)
60. Georgescu MM, Kirsch KH, Kaloudis P, Yang H, Pavletich NP, Hanafusa H (2000) Stabilization and productive positioning roles of the C2 domain of PTEN tumor suppressor. Cancer Res 60:7033-7038 (Pubitemid 32059181)
61. Goel VK, Ibrahim N, Jiang G, Singhal M, Fee S, Flotte T, Westmoreland S, Haluska FS, Hinds PW, Haluska FG (2009) Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice. Oncogene 28:2289-2298
62. Goffin A, Hoefsloot LH, Bosgoed E, Swillen A, Fryns JP (2001) PTEN mutation in a family with Cowden syndrome and autism. Am J Med Genet 105:521-524 (Pubitemid 32729819)
63. Gray IC, Stewart LM, Phillips SM, Hamilton JA, Gray NE, Watson GJ, Spurr NK, Snary D (1998) Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN. Br J Cancer 78:1296-1300 (Pubitemid 28495240)
64. Groszer M, Erickson R, Scripture-Adams DD, Lesche R, Trumpp A, Zack JA, Kornblum HI, Liu X, Wu H (2001) Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science 294:2186-2189 (Pubitemid 33150679)
65. Groszer M, Erickson R, Scripture-Adams DD, Dougherty JD, Le Belle J, Zack JA, Geschwind DH, Liu X, Kornblum HI, Wu H (2006) PTEN negatively regulates neural stem cell self-renewal by modulating G0-G1 cell cycle entry. Proc Natl Acad Sci USA 103:111-116 (Pubitemid 43076113)
66. Gudmundsson J, Sulem P, Manolescu A, Amundadottir LT, Gudbjartsson D, Helgason A, Rafnar T, Bergthorsson JT, Agnarsson BA, Baker A et al (2007) Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 39:631-637 (Pubitemid 46676102)
67. Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12:9-22 (Pubitemid 47001784)
68. Guertin DA, Stevens DM, Saitoh M, Kinkel S, Crosby K, Sheen JH, Mullholland DJ, Magnuson MA, Wu H, Sabatini DM (2009) mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 15:148-159
69. Gupta S, Ramjaun AR, Haiko P, Wang Y, Warne PH, Nicke B, Nye E, Stamp G, Alitalo K, Downward J (2007) Binding of ras to phosphoinositide 3-kinase p110alpha is required for rasdriven tumorigenesis in mice. Cell 129:957-968 (Pubitemid 46802703)
70. Gurel B, Iwata T, Koh CM, Jenkins RB, Lan F, Van Dang C, Hicks JL, Morgan J, Cornish TC, Sutcliffe S, Isaacs WB, Luo J, De Marzo AM (2008) Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol 21:1156-1167
71. Hagenbeek TJ, Naspetti M, Malergue F, Garcon F, Nunes JA, Cleutjens KB, Trapman J, Krimpenfort P, Spits H (2004) The loss of PTEN allows TCR alphabeta lineage thymocytes to bypass IL-7 and Pre-TCR-mediated signaling. J Exp Med 200(7):883-894 (Pubitemid 39362924)
72. Hagenbeek TJ, Spits H (2008) T-cell lymphomas in T-cell-specific Pten-deficient mice originate in the thymus. Leukemia 22(3):608-619 (Pubitemid 351386732)
73. Haiman CA, Patterson N, Freedman ML, Myers SR, Pike MC, Waliszewska A, Neubauer J, Tandon A, Schirmer C, McDonald GJ et al (2007) Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet 39:638-644 (Pubitemid 46676106)
74. Halilovic E, Solit DB (2008) Therapeutic strategies for inhibiting oncogenic BRAF signaling. Curr Opin Pharmacol 8:419-426
75. Haluska FG, Tsao H, Wu H, Haluska FS, Lazar A, Goel V (2006) Genetic alterations in signaling pathways in melanoma. Clin Cancer Res 12:2301s-2307s
76. Hamada K, Sasaki T, Koni PA, Natsui M, Kishimoto H, Sasaki J, Yajima N, Horie Y, Hasegawa G, Naito M et al (2005) The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis. Genes Dev 19(17):2054-2065 (Pubitemid 41247962)
77. Han S, Ritzenthaler JD, Zheng Y, Roman J (2008) PPAR{beta}/{delta}agonist stimulates human lung carcinoma cell growth through inhibition of PTEN expression: the involvement of PI3-K and NF-{kappa}B signals. Am J Physiol Lung Cell Mol Physiol 294:L1238-L1249
78. Herman GE, Butter E, Enrile B, Pastore M, Prior TW, Sommer A (2007) Increasing knowledge of PTEN germline mutations: Two additional patients with autism and macrocephaly. Am J Med Genet A 143:589-593 (Pubitemid 46348901)
79. Hernando E, Charytonowicz E, Dudas ME, Menendez S, Matushansky I, Mills J, Socci ND, Behrendt N, Ma L, Maki RG, Pandolfi PP, Cordon-Cardo C (2007) The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med 13:748-753 (Pubitemid 46889749)
80. Horie Y, Suzuki A, Kataoka E, Sasaki T, Hamada K, Sasaki J, Mizuno K, Hasegawa G, Kishimoto H, Iizuka M, Naito M, Enomoto K, Watanabe S, Mak TW, Nakano T (2004) Hepatocytespecific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest 113:1774-1783 (Pubitemid 39071669)
81. Iida S, Tanaka Y, Fujii H, Hayashi S, Kimura M, Nagareda T, Moriwaki K (1998) A heterozygous frameshift mutation of the PTEN/MMAC1 gene in a patient with Lhermitte-Duclos disease -only the mutated allele was expressed in the cerebellar tumor. Int J Mol Med 1:925-929
82. Iida S, Ono A, Sayama K, Hamaguchi T, Fujii H, Nakajima H, Namba M, Hanafusa T, Matsuzawa Y, Moriwaki K (2000) Accelerated decline of blood glucose after intravenous glucose injection in a patient with Cowden disease having a heterozygous germline mutation of the PTEN/ MMAC1 gene. Anticancer Res 20:1901-1904 (Pubitemid 30636155)
83. Inoki K, Li Y, Xu T, Guan KL (2003) Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 17:1829-1834 (Pubitemid 36944560)
84. Inoue-Narita T, Hamada K, Sasaki T, Hatakeyama S, Fujita S, Kawahara K, Sasaki M, Kishimoto H, Eguchi S, Kojima I et al (2008) Pten deficiency in melanocytes results in resistance to hairgraying and susceptibility to carcinogen-induced melanomagenesis. Cancer Res 68(14):5760-5768
85. Jaeschke A, Hartkamp J, Saitoh M, Roworth W, Nobukuni T, Hodges A, Sampson J, Thomas G, Lamb R (2002) Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent. J Cell Biol 159:217-224 (Pubitemid 35283391)
86. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005) Cancer statistics, 2005. CA Cancer J Clin 55:10-30 (Pubitemid 40310185)
87. Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, Zhang J, Signoretti S, Loda M, Roberts TM, Zhao JJ (2008) Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 454:776-779
88. Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA, Jacks T (2001) Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410:1111-1116 (Pubitemid 32391044)
89. Kato H, Kato S, Kumabe T, Sonoda Y, Yoshimoto T, Han SY, Suzuki T, Shibata H, Kanamaru R, Ishioka C (2000) Functional evaluation of p53 and PTEN gene mutations in gliomas. Clin Cancer Res 6:3937-3943
90. Kim J, Eltoum IE, Roh M, Wang J, Abdulkadir SA (2009) Interactions between cells with distinct mutations in c-MYC and Pten in prostate cancer. PLoS Genet 5:e1000542
91. Kimura T, Suzuki A, Fujita Y, Yomogida K, Lomeli H, Asada N, Ikeuchi M, Nagy A, Mak TW, Nakano T (2003) Conditional loss of PTEN leads to testicular teratoma and enhances embryonic germ cell production. Development 130:1691-1700 (Pubitemid 36527527)
92. Klinghoffer RA, Duckworth B, Valius M, Cantley L, Kazlauskas A (1996) Platelet-derived growth factor-dependent activation of phosphatidylinositol 3-kinase is regulated by receptor binding of SH2-domain-containing proteins which influence Ras activity. Mol Cell Biol 16:5905-5914 (Pubitemid 26315112)
93. Knobbe CB, Merlo A, Reifenberger G (2002) Pten signaling in gliomas. Neuro Oncol 4:196-211
94. Koul A, Willen R, Bendahl PO, Nilbert M, Borg A (2002) Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis. Cancer 94:2369-2379 (Pubitemid 34457118)
95. Kurlawalla-Martinez C, Stiles B, Wang Y, Devaskar SU, Kahn BB, Wu H (2005) Insulin hypersensitivity and resistance to streptozotocin-induced diabetes in mice lacking PTEN in adipose tissue. Mol Cell Biol 25(6):2498-2510 (Pubitemid 40354642)
96. Kuroda S, Nishio M, Sasaki T, Horie Y, Kawahara K, Sasaki M, Natsui M, Matozaki T, Tezuka H, Ohteki T, Forster, I, Mak TW, Nakano T, Suzuki A (2008) Effective clearance of intracellular Leishmania major in vivo requires Pten in macrophages. Eur J Immunol 38 (5):1331-1340
97. Kurose K, Gilley K, Matsumoto S, Watson PH, Zhou XP, Eng C (2002) Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat Genet 32:355-357 (Pubitemid 35266108)
98. Kwon CH, Zhu X, Zhang J, Knoop LL, Tharp R, Smeyne RJ, Eberhart CG, Burger PC, Baker SJ (2001) Pten regulates neuronal soma size: a mouse model of Lhermitte-Duclos disease. Nat Genet 29:404-411 (Pubitemid 34326690)
99. Kwon CH, Luikart BW, Powell CM, Zhou J, Matheny SA, Zhang W, Li Y, Baker SJ, Parada LF (2006) Pten regulates neuronal arborization and social interaction in mice. Neuron 50:377-388
100. Levine AJ, Finlay CA, Hinds PW (2004) P53 is a tumor suppressor gene. Cell 116:S67-S69, 61 p following S69
101. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943-1947 (Pubitemid 27148818)
102. Li G, Robinson GW, Lesche R, Martinez-Diaz H, Jiang Z, Rozengurt N, Wagner KU, Wu DC, Lane TF, Liu X, Hennighausen L, Wu H (2002) Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development 129:4159-4170 (Pubitemid 35012500)
103. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, Bose S, Call KM, Tsou HC, Peacocke M, Eng C, Parsons R (1997) Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16:64-67 (Pubitemid 27198157)
104. Lin WM, Forgacs E, Warshal DP, Yeh IT, Martin JS, Ashfaq R, Muller CY (1998) Loss of heterozygosity and mutational analysis of the PTEN/MMAC1 gene in synchronous endometrial and ovarian carcinomas. Clin Cancer Res 4:2577-2583 (Pubitemid 28523482)
105. Liu W, James CD, Frederick L, Alderete BE, Jenkins RB (1997) PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. Cancer Res 57:5254-5257 (Pubitemid 27516358)
106. Liu X, Bruxvoort KJ, Zylstra CR, Liu J, Cichowski R, Faugere MC, Bouxsein ML, Wan C, Williams BO, Clemens TL (2007) Lifelong accumulation of bone in mice lacking Pten in osteoblasts. Proc Natl Acad Sci USA 104(7):2259-2264 (Pubitemid 46391385)
107. Luchman HA, Benediktsson H, Villemaire ML, Peterson AC, Jirik FR (2008) The pace of prostatic intraepithelial neoplasia development is determined by the timing of Pten tumor suppressor gene excision. PLoS One 3:e3940
108. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP (2005a) Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121:179-193 (Pubitemid 40546387)
109. Ma L, Teruya-Feldstein J, Behrendt N, Chen Z, Noda T, Hino O, Cordon-Cardo C, Pandolfi PP (2005b) Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression. Genes Dev 19:1779-1786 (Pubitemid 41126917)
110. Ma X, Ziel-van der Made AC, Autar B, van der Korput HA, Vermeij M, van Duijn P, Cleutjens KB, de Krijger R, Krimpenfort P, Berns A, van der Kwast TH, Trapman J (2005c) Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. Cancer Res 65:5730-5739 (Pubitemid 40911176)
111. Maehama T, Dixon JE (1998) The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273:13375-13378 (Pubitemid 28268370)
112. Manning BD, Cantley LC (2007) AKT/PKB signaling: navigating downstream. Cell 129:1261-1274 (Pubitemid 46962095)
113. Manning BD, Logsdon MN, Lipovsky AI, Abbott D, Kwiatkowski DJ, Cantley LC (2005) Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev 19:1773-1778 (Pubitemid 41126916)
114. Marandola P, Bonghi A, Jallous H, Bombardelli E, Morazzoni P, Gerardini M, Tiscione D, Albergati F (2004) Molecular biology and the staging of prostate cancer. Ann N Y Acad Sci 1028:294-312 (Pubitemid 40361831)
115. Marino S, Krimpenfort P, Leung C, van der Korput HA, Trapman J, Camenisch I, Berns A, Brandner S (2002) PTEN is essential for cell migration but not for fate determination and tumourigenesis in the cerebellum. Development 129:3513-3522
116. Marsh DJ, Dahia PL, Zheng Z, Liaw D, Parsons R, Gorlin RJ, Eng C (1997) Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet 16:333-334
117. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, Majoor DM, Shay JW, Mooi WJ, Peeper DS (2005) BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436:720-724 (Pubitemid 41117276)
118. Moodie SA, Willumsen BM, Weber MJ, Wolfman A (1993) Complexes of Ras.GTP with Raf-1 and mitogen-activated protein kinase kinase. Science 260:1658-1661 (Pubitemid 23247150)
119. Nardella C, Chen Z, Salmena L, Carracedo A, Alimonti A, Egia A, Carver B, Gerald W, Cordon-Cardo C, Pandolfi PP (2008) Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events. Genes Dev 22:2172-2177
120. Nardella C, Carracedo A, Alimonti A, Hobbs RM, Clohessy JG, Chen Z, Egia A, Fornari A, Fiorentino M, Loda M, Kozma SC, Thomas G, Cordon-Cardo C, Pandolfi PP (2009) Differential requirement of mTOR in postmitotic tissues and tumorigenesis. Sci Signal 2:ra2
121. Nguyen KT, Tajmir P, Lin CH, Liadis N, Zhu XD, Eweida M, Tolasa-Karaman G, Cai F, Wang R, Kitamura T et al (2006) Essential role of Pten in body size determination and pancreatic betacell homeostasis in vivo. Mol Cell Biol 26(12):4511-4518 (Pubitemid 43877571)
122. Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, De Marzo AM, Rubin MA (2007) TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 31:882-888 (Pubitemid 47165141)
123. Perren A, Weng LP, Boag AH, Ziebold U, Thakore K, Dahia PL, Komminoth P, Lees JA, Mulligan LM, Mutter GL, Eng C (1999) Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 155:1253-1260 (Pubitemid 29488932)
124. Plum L, Ma X, Hampel B, Balthasar N, Coppari R, Munzberg H, Shanabrough M, Burdakov D, Rother E, Janoschek R et al (2006) Enhanced PIP3 signaling in POMC neurons causes KATP channel activation and leads to diet-sensitive obesity. J Clin Invest 116(7):1886-1901 (Pubitemid 44033313)
125. Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, Cordon-Cardo C, Catoretti G, Fisher PE, Parsons R (1999) Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 96:1563-1568 (Pubitemid 29098491)
126. Poliseno L, Salmena L, Riccardi L, Fornari A, Song MS, Hobbs RM, Sportoletti P, Varmeh S, Egia A, Fedele G, Rameh L, Loda M, Pandolfi PP (2010) Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal 3(117):ra29
127. Pomerantz MM, Beckwith CA, Regan MM, Wyman SK, Petrovics G, Chen Y, Hawksworth DJ, Schumacher FR, Mucci L, Penney KL et al (2009) Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res 69:5568-5574
128. Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, Wang X, Shen TH, Matos T, Shen MM, Cordon-Cardo C, Abate-Shen C (2009) Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev 23:675-680
129. Qian J, Jenkins RB, Bostwick DG (1997) Detection of chromosomal anomalies and c-myc gene amplification in the cribriform pattern of prostatic intraepithelial neoplasia and carcinoma by fluorescence in situ hybridization. Mod Pathol 10:1113-1119 (Pubitemid 27521289)
130. Rasheed BK, Stenzel TT, McLendon RE, Parsons R, Friedman AH, Friedman HS, Bigner DD, Bigner SH (1997) PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res 57:4187-4190 (Pubitemid 27413420)
131. Ratnacaram CK, Teletin M, Jiang M, Meng X, Chambon P, Metzger D (2008) Temporally controlled ablation of PTEN in adult mouse prostate epithelium generates a model of invasive prostatic adenocarcinoma. Proc Natl Acad Sci USA 105:2521-2526 (Pubitemid 351520546)
132. Reddy P, Liu L, Adhikari D, Jagarlamudi K, Rajareddy S, Shen Y, Du C, Tang W, Hamalainen T, Peng SL et al (2008) Oocyte-specific deletion of Pten
133. Rubin MA, Gerstein A, Reid K, Bostwick DG, Cheng L, Parsons R, Papadopoulos N (2000) 10q23.3 loss of heterozygosity is higher in lymph node-positive (pT2-3, N+) versus lymph node-negative (pT2-3, N0) prostate cancer. Hum Pathol 31:504-508 (Pubitemid 30262874)
134. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malmstrom PO, Mansukhani M, Enoksson J, Hibshoosh H, Borg A, Parsons R (2005) PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65:2554-2559 (Pubitemid 40490050)
135. Saal LH, Gruvberger-Saal SK, Persson C, Lovgren K, Jumppanen M, Staaf J, Jonsson G, Pires MM, Maurer M, Holm K et al (2008) Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet 40:102-107
136. Salmena L, Carracedo A, Pandolfi PP (2008) Tenets of PTEN tumor suppression. Cell 133:403-414 (Pubitemid 351622014)
137. Samuels Y, Velculescu VE (2004) Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 3:1221-1224 (Pubitemid 40268595)
138. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/ PKB by the rictor-mTOR complex. Science 307:1098-1101 (Pubitemid 40262113)
139. Schrager CA, Schneider D, Gruener AC, Tsou HC, Peacocke M (1998) Clinical and pathological features of breast disease in Cowden's syndrome: an underrecognized syndrome with an increased risk of breast cancer. Hum Pathol 29:47-53 (Pubitemid 28049545)
140. Shao X, Tandon R, Samara G, Kanki H, Yano H, Close LG, Parsons R, Sato T (1998) Mutational analysis of the PTEN gene in head and neck squamous cell carcinoma. Int J Cancer 77:684-688 (Pubitemid 28341383)
141. Simpson L, Parsons R (2001) PTEN: life as a tumor suppressor. Exp Cell Res 264:29-41 (Pubitemid 32989079)
142. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869-10874 (Pubitemid 32878711)
143. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP, Mak TW (1998) Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95:29-39 (Pubitemid 28458022)
144. Stanger BZ, Stiles B, Lauwers GY, Bardeesy N, Mendoza M, Wang Y, Greenwood A, Cheng KH, McLaughlin M, Brown D et al (2005) Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell 8(3):185-195 (Pubitemid 41317590)
145. Stambolic V, Tsao MS, Macpherson D, Suzuki A, Chapman WB, Mak TW (2000) High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/-mice. Cancer Res 60:3605-3611 (Pubitemid 30482183)
146. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH, Tavtigian SV (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15:356-362 (Pubitemid 27147102)
147. Stiles B, Wang Y, Stahl A, Bassilian S, Lee WP, Kim YJ, Sherwin R, Devaskar S, Lesche R, Magnuson MA, Wu H (2004) Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected]. Proc Natl Acad Sci USA 101:2082-2087 (Pubitemid 38229018)
148. Stiles BL, Kuralwalla-Martinez C, Guo W, Gregorian C, Wang Y, Tian J, Magnuson MA, Wu H (2006) Selective deletion of Pten in pancreatic beta cells leads to increased islet mass and resistance to STZ-induced diabetes. Mol Cell Biol 26:2772-2781
149. Subramanian KK, Jia Y, Zhu D, Simms BT, Jo H, Hattori H, You J, Mizgerd JP, Luo HR (2007) Tumor suppressor PTEN is a physiologic suppressor of chemoattractant-mediated neutrophil functions. Blood 109(9):4028-4037 (Pubitemid 46641758)
150. SuzukiA, de la Pompa JL, StambolicV, Elia AJ, Sasaki T, del Barco Barrantes I,HoA,WakehamA, Itie A, Khoo W, FukumotoM,Mak TW(1998)High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol 8:1169-1178 (Pubitemid 28494715)
151. Suzuki A, Hamada K, Sasaki T, Mak TW, Nakano T (2007) Role of PTEN/PI3K pathway in endothelial cells. Biochem Soc Trans 35(Pt 2):172-176 (Pubitemid 46596460)
152. Suzuki A, Itami S, Ohishi M, Hamada K, Inoue T, Komazawa N, Senoo H, Sasaki T, Takeda J, Manabe M, Mak TW, Nakano T (2003) Keratinocyte-specific Pten deficiency results in epidermal hyperplasia, accelerated hair follicle morphogenesis and tumor formation. Cancer Res 63(3):674-681 (Pubitemid 36158147)
153. Suzuki A, Sasaki T, Mak TW, Nakano T (2004) Functional analysis of the tumour suppressor gene PTEN in murine B cells and keratinocytes. Biochem Soc Trans 32:362-365 (Pubitemid 38582129)
154. Suzuki A, Yamaguchi MT, Ohteki T, Sasaki T, Kaisho T, Kimura Y, Yoshida R, Wakeham A, Higuchi T, Fukumoto M et al (2001) T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity 14(5):523-534 (Pubitemid 32520864)
155. Tapon N, Ito N, Dickson BJ, Treisman JE, Hariharan IK (2001) The Drosophila tuberous sclerosis complex gene homologs restrict cell growth and cell proliferation. Cell 105:345-355 (Pubitemid 32455341)
156. Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI, Li J, Parsons R, Ellenson LH (1997) Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 57:3935-3940 (Pubitemid 27427679)
157. Taube JM, Begum S, Shi C, Eshleman JR, Westra WH (2009) Benign nodal nevi frequently harbor the activating V600E BRAF mutation. Am J Surg Pathol 33:568-571
158. Tee AR, Fingar DC,Manning BD, Kwiatkowski DJ, Cantley LC, Blenis J (2002) Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci USA 99:13571-13576 (Pubitemid 35215423)
159. TengDH, Hu R, Lin H, Davis T, Iliev D, Frye C, Swedlund B, Hansen KL, VinsonVL, Gumpper KL et al (1997) MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 57:5221-5225 (Pubitemid 27516352)
160. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310:644-648 (Pubitemid 41528150)
161. Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A, Khoo AS, Roy-Burman P, Greenberg NM, Van Dyke T, Cordon-Cardo C, Pandolfi PP (2003) Pten dose dictates cancer progression in the prostate. PLoS Biol 1:E59
162. Tsao H, Zhang X, Fowlkes K, Haluska FG (2000) Relative reciprocity of NRAS and PTEN/ MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res 60:1800-1804 (Pubitemid 30207633)
163. Tsuchiya N, Kondo Y, Takahashi A, Pawar H, Qian J, Sato K, Lieber MM, Jenkins RB (2002) Mapping and gene expression profile of the minimally overrepresented 8q24 region in prostate cancer. Am J Pathol 160:1799-1806 (Pubitemid 34525659)
164. Tsuruta H, Kishimoto H, Sasaki T, Horie Y, Natsui M, Shibata Y, Hamada K, Yajima N, Kawahara K, Sasaki M et al (2006) Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients. Cancer Res 66(17):8389-8396 (Pubitemid 44449149)
165. Vasudevan KM, Burikhanov R, Goswami A, Rangnekar VM (2007) Suppression of PTEN expression is essential for antiapoptosis and cellular transformation by oncogenic Ras. Cancer Res 67:10343-10350 (Pubitemid 350070809)
166. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408:307-310
167. Wang SI, Puc J, Li J, Bruce JN, Cairns P, Sidransky D, Parsons R (1997) Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 57:4183-4186 (Pubitemid 27413419)
168. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, Thomas GV, Li G, Roy-Burman P, Nelson PS, Liu X, Wu H (2003) Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4:209-221 (Pubitemid 37163835)
169. Wiencke JK, Zheng S, Jelluma N, Tihan T, Vandenberg S, Tamguney T, Baumber R, Parsons R, Lamborn KR, Berger MS, Wrensch MR, Haas-Kogan DA, Stokoe D (2007) Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. Neuro Oncol 9:271-279 (Pubitemid 47169659)
170. Wijesekara N, Konrad D, Eweida M, Jefferies C, Liadis N, Giacca A, Crackower M, Suzuki A, Mak TW, Kahn CR, Klip A, Woo M (2005) Muscle-specific Pten deletion protects against insulin resistance and diabetes. Mol Cell Biol 25(3):1135-1145 (Pubitemid 40165819)
171. Witte JS (2007) Multiple prostate cancer risk variants on 8q24. Nat Genet 39:579-580 (Pubitemid 46676095)
172. Wu X, Wu J, Huang J, Powell WC, Zhang J, Matusik RJ, Sangiorgi FO, Maxson RE, Sucov HM, Roy-Burman P (2001) Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev 101:61-69 (Pubitemid 32186310)
173. Wullschleger S, Loewith R, Hall MN (2006) TOR signaling in growth and metabolism. Cell 124:471-484 (Pubitemid 43199434)
174. Yanagi S, Kishimoto H, Kawahara K, Sasaki T, Sasaki M, Nishio M, Yajima N, Hamada K, Horie Y, Kubo H, Whitsett JA, Mak TW, Nakano T, Nakazato M, Suzuki A (2007) Pten controls lung morphogenesis, bronchioalveolar stem cells, and onset of lung adenocarcinomas in mice. J Clin Invest 117(10):2929-2940 (Pubitemid 47529623)
175. Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, Cheng JQ (2008) MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 68:425-433 (Pubitemid 351380068)
176. Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P,Wacholder S, MinichielloMJ, Fearnhead P, Yu K, Chatterjee N et al (2007) Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 39:645-649 (Pubitemid 46676108)
177. Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferguson DO, Wu H, Morrison SJ (2006) Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441:475-482 (Pubitemid 44050144)
178. Yoo LI, Liu DW, Le Vu S, Bronson RT, Wu H, Yuan J (2006) Pten deficiency activates distinct downstream signaling pathways in a tissue-specific manner. Cancer Res 66(4):1929-1939
179. Yue Q, Groszer M, Gil JS, Berk AJ, Messing A, Wu H, Liu X (2005) PTEN deletion in Bergmann glia leads to premature differentiation and affects laminar organization. Development 132:3281-3291 (Pubitemid 41167155)
180. Zhang J, Grindley JC, Yin T, Jayasinghe S, He XC, Ross JT, Haug JS, Rupp D, Porter-Westpfahl KS, Wiedemann LM, Wu H, Li L (2006) PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 441(7092):518-522 (Pubitemid 44050154)
181. Zhang X, Lee C, Ng PY, Rubin M, Shabsigh A, Buttyan R (2000) Prostatic neoplasia in transgenic mice with prostate-directed overexpression of the c-myc oncoprotein. Prostate 43:278-285 (Pubitemid 30367963)
182. Zhang Y, Gao X, Saucedo LJ, Ru B, Edgar BA, Pan D (2003) Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol 5:578-581 (Pubitemid 36781094)
183. Zheng H,YingH,Yan H, Kimmelman AC, Hiller DJ, Chen AJ, Perry SR, Tonon G, Chu GC, Ding Z et al (2008) p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 455:1129-1133
184. Zhou XP, Marsh DJ, Hampel H, Mulliken JB, Gimm O, Eng C (2000) Germline and germline mosaic PTEN mutations associated with a Proteus-like syndrome of hemihypertrophy, lower limb asymmetry, arteriovenous malformations and lipomatosis. Hum Mol Genet 9:765-768 (Pubitemid 30162760)
185. Zhou X, Hampel H, Thiele H, Gorlin RJ, Hennekam RC, Parisi M, Winter RM, Eng C (2001) Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes. Lancet 358:210-211 (Pubitemid 32718548)
186. Zhou XP, Kuismanen S, Nystrom-Lahti M, Peltomaki P, Eng C (2002) Distinct PTEN mutational spectra in hereditary non-polyposis colon cancer syndrome-related endometrial carcinomas compared to sporadic microsatellite unstable tumors. Hum Mol Genet 11:445-450 (Pubitemid 34213618)
187. Zhou XP, Marsh DJ, Morrison CD, Chaudhury AR, Maxwell M, Reifenberger G, Eng C (2003) Germline inactivation of PTEN and dysregulation of the phosphoinositol-3-kinase/Akt pathway cause human Lhermitte-Duclos disease in adults. Am J Hum Genet 73:1191-1198 (Pubitemid 37414231)
188. Zhu D, Hattori H, Jo H, Jia Y, Subramanian KK, Loison F, You J, Le Y, Honczarenko M, Silberstein L, Luo HR (2006) Deactivation of phosphatidylinositol 3,4,5-trisphosphate/Akt signaling mediates neutrophil spontaneous death. Proc Natl Acad Sci USA 103(40):14836-14841 (Pubitemid 44527815)